Stockreport
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
TARRYTOWN, N.Y., March 17, 2020 /PRNewswire/ -- Regeneron has identified hundreds of virus-neutralizing antibodies; plans to initiate large-scale manufacturing by mid-April with antibody cocktail therapyPotential to enter human clinical studies by early summerThis program is in addition to Regeneron's separate ongoing clinical program evaluating Kevzara® (sarilumab, an IL-6 receptor antibody) in severe COVID-19 patientsRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated hundreds of virus-neutralizing, fully human antibodies from the company's VelocImmune® mice, which have been genetically-modified to have a human immune system. Regeneron has also isolated antibodies from humans who have recovered from COVID-19, in order to m
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry? [Yahoo! Finance][Yahoo! Finance]
- REGN CRUCIAL INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm[Accesswire]
- Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings[Accesswire]
- Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance][Yahoo! Finance]
- Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings[Accesswire]
- More
REGN
SEC Filings
SEC Filings
- 6/3/24 - Form 144
- 5/29/24 - Form 4
- 5/28/24 - Form 144
- REGN's page on the SEC website
- More